FDA: Spiriva HandiHaler doesn't increase stroke or heart risks

01/14/2010 | Wall Street Journal, The

The FDA concluded that clinical data show no concrete evidence that Spiriva HandiHaler heightens the risk of stroke or cardiovascular problems in patients with chronic obstructive pulmonary disease. The product, which is owned by Boehringer Ingelheim and Pfizer, underwent a government investigation in 2008 because of stroke concerns.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager, Business Conduct
Gilead
Foster City, CA
Product Patent Attorney
Gilead
Foster City, CA
Employment Counsel
Gilead
Foster City, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Global Counsel - Advertising and Promotions
Mylan Inc.
Washington, DC